Envision Healthcare Corporation (EVHC) PT Set at $67.00 by KeyCorp

KeyCorp set a $67.00 price target on Envision Healthcare Corporation (NYSE:EVHC) in a research note published on Wednesday, November 1st. The brokerage currently has a buy rating on the stock.

Several other equities analysts have also recently issued reports on the stock. Robert W. Baird reiterated a buy rating and set a $70.00 price target on shares of Envision Healthcare Corporation in a research report on Tuesday, October 17th. Cantor Fitzgerald reiterated a buy rating and set a $80.00 price target on shares of Envision Healthcare Corporation in a research report on Tuesday, July 4th. Zacks Investment Research upgraded shares of Envision Healthcare Corporation from a strong sell rating to a buy rating and set a $70.00 price target on the stock in a research report on Tuesday, July 4th. Jefferies Group LLC set a $71.00 price target on shares of Envision Healthcare Corporation and gave the company a buy rating in a research report on Thursday, August 24th. Finally, BidaskClub lowered shares of Envision Healthcare Corporation from a hold rating to a sell rating in a research note on Tuesday, August 1st. Two research analysts have rated the stock with a sell rating, five have given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of Buy and a consensus target price of $49.21.

Shares of Envision Healthcare Corporation (NYSE:EVHC) opened at $24.95 on Wednesday. The stock has a market cap of $3,016.19, a price-to-earnings ratio of 7.70, a PEG ratio of 0.65 and a beta of 0.69. Envision Healthcare Corporation has a fifty-two week low of $24.45 and a fifty-two week high of $74.75. The company has a current ratio of 3.01, a quick ratio of 3.00 and a debt-to-equity ratio of 0.89.

Envision Healthcare Corporation (NYSE:EVHC) last issued its earnings results on Tuesday, October 31st. The company reported $0.73 EPS for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.08). The business had revenue of $1.99 billion during the quarter, compared to analysts’ expectations of $2.03 billion. Envision Healthcare Corporation had a positive return on equity of 4.88% and a negative net margin of 6.39%. Envision Healthcare Corporation’s revenue for the quarter was up 142.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.13 EPS. research analysts predict that Envision Healthcare Corporation will post 2.56 earnings per share for the current fiscal year.

WARNING: This piece of content was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://ledgergazette.com/2017/11/13/keycorp-analysts-give-envision-healthcare-corporation-evhc-a-67-00-price-target.html.

Envision Healthcare Corporation declared that its Board of Directors has authorized a share buyback plan on Monday, September 18th that authorizes the company to buyback $250.00 million in outstanding shares. This buyback authorization authorizes the company to buy up to 4.5% of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s leadership believes its shares are undervalued.

A number of institutional investors have recently modified their holdings of the stock. Schwab Charles Investment Management Inc. lifted its position in Envision Healthcare Corporation by 6.7% during the third quarter. Schwab Charles Investment Management Inc. now owns 674,538 shares of the company’s stock valued at $30,321,000 after purchasing an additional 42,343 shares during the period. Wells Fargo & Company MN lifted its position in Envision Healthcare Corporation by 11.2% during the third quarter. Wells Fargo & Company MN now owns 917,418 shares of the company’s stock valued at $41,238,000 after purchasing an additional 92,339 shares during the period. Achmea Investment Management B.V. lifted its position in Envision Healthcare Corporation by 433.8% during the third quarter. Achmea Investment Management B.V. now owns 16,226 shares of the company’s stock valued at $729,000 after purchasing an additional 13,186 shares during the period. Pegasus Partners Ltd. lifted its position in Envision Healthcare Corporation by 51.7% during the third quarter. Pegasus Partners Ltd. now owns 80,646 shares of the company’s stock valued at $3,625,000 after purchasing an additional 27,473 shares during the period. Finally, JPMorgan Chase & Co. lifted its position in Envision Healthcare Corporation by 420.6% during the third quarter. JPMorgan Chase & Co. now owns 592,805 shares of the company’s stock valued at $26,083,000 after purchasing an additional 478,926 shares during the period.

Envision Healthcare Corporation Company Profile

Envision Healthcare Holdings, Inc, formerly CDRT Holding Corporation, is a holding company. The Company, through its subsidiary, provides physician-led medical services in the United States. It operates in two segments: EmCare Holdings, Inc (EmCare) and American Medical Response, Inc (AMR). Its EmCare segment is a provider of integrated facility-based and post-acute care physician services to healthcare facilities in the United States.

Analyst Recommendations for Envision Healthcare Corporation (NYSE:EVHC)

Receive News & Ratings for Envision Healthcare Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envision Healthcare Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply